The Board of Directors of CELLINK AB (publ) has, based on the authorization given by the Company’s Annual General Meeting that was held on 18 December 2019, resolved on a directed share issue of 3,890,000 new shares of series B (corresponding to approximately 10 per cent of the total number of outstanding shares in the Company) at a subscription price of SEK 97 per share (the “Share Issue”), which means that the Company receives SEK 377,330,000 before transaction costs.
Pathios Therapeutics Limited, an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare investors Canaan and Australia’s Medical Research Commercialization Fund managed by Brandon Capital.
The community of preclinical immuno-oncology scientific Pharma and Biotechs meet again to advance their preclinical insights through robust models utilization to accelerate IO development & clinical confidence.
SP Industries, Inc., a leading designer and manufacturer of state-of-the-art laboratory equipment, pharmaceutical fill-finish manufacturing solutions, laboratory supplies and glassware, announced today that it has acquired the assets of privately held i-Dositecno.
Join us in Chicago, Illinois from March 1-5, 2020 to focus on the latest research, instrumentation, techniques, and collaboration.
Olympus Corporation today announced its Corporate Strategy in central Tokyo. The announcement follows the company's earlier announcement in January this year, when significant changes in governance, the headquarters move of the Therapeutic Solutions business to the US, as well as a cost containment program were announced as a starting point of the company's extensive transformation efforts.
Grundium, a technology company in the digital pathology sphere, has entered into a major dealership contract with Alliance Global Group.
Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for third quarter 2019 after the close of trading on Wednesday, November 6, 2019.
Mogrify Ltd (Mogrify), a UK company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over $20 million USD to date.
Enable Injections, Inc., a company developing and manufacturing investigational wearable infusion devices for combination products, today announced it has entered into a development agreement with Genentech, a member of the Roche Group. The enFuseTM, under development by Enable, will enable patient-administered subcutaneous delivery of high-volume therapeutics.
Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the closing of its previously announced underwritten public offering of 2,732,673 shares of its common stock at a public offering price of $25.25 per share, including 356,435 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares.
Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the pricing of its previously announced underwritten public offering of 2,376,238 shares of its common stock at a public offering price of $25.25 per share.
Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock.